Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP, CHIEF COMMERCIAL OFFICER | March 08, 2017 | March 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date March 08, 2017 · Filed March 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.54 · Expires 2027-03-07 | Direct | 33,750 |
Reported balance
After 2017-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-08 · Grant · Acquired 33,750 · Balance 33,750 F1: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2017 Filed Mar 11, 2017 01:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000407 · form4-03102017_050310.xml · derivative · entry 1 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 7,856 | $0.00 Strike: $34.45 | $0.00 |
DisclosureSEC source: 0001415889-17-000308 · form4-02232017_030207.xml · derivative · entry 3 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 7,856 shares Expires 2025-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 7,856 | $39.65 | $311,490.40 |
DisclosureSEC source: 0001415889-17-000308 · form4-02232017_030207.xml · nonDerivative · entry 2 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. All sales under the trading plan have been completed. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 7,856 | $34.45 | $270,639.20 |
DisclosureSEC source: 0001415889-17-000308 · form4-02232017_030207.xml · nonDerivative · entry 1 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 29,644 | $0.00 Strike: $34.35 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 14 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,356 Underlying: Common Stock · 29,644 shares Expires 2025-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 19,687 | $0.00 Strike: $27.20 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 13 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 19,687 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 17,421 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 12 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,102 Underlying: Common Stock · 17,421 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 66,752 | $39.88 | $2,662,116.49 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 8 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 29,644 | $34.45 | $1,021,235.80 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 7 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 19,687 | $27.20 | $535,486.40 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 6 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 17,421 | $19.61 | $341,625.81 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 5 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 11 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,523 Underlying: Common Stock · 1,700 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,700 | $39.65 | $67,405.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 4 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,700 | $19.61 | $33,337.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 3 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 74,381 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 10 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,223 Underlying: Common Stock · 74,381 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 12,747 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · derivative · entry 9 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,649 Underlying: Common Stock · 12,747 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 89,088 | $39.69 | $3,535,573.09 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 2 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 87,128 | $19.61 | $1,708,580.08 |
DisclosureSEC source: 0001415889-17-000282 · form4-02162017_040225.xml · nonDerivative · entry 1 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.